Hidradenitis suppurativa
Drug research and approvals for hidradenitis suppurativa: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 57 studies of hidradenitis suppurativa are recruiting on ClinicalTrials.gov, Health Canada has authorized 57 drug trials for it since 2013, FDA has 2 approved and 0 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 57
- Trials authorized in Canada: 57
- FDA orphan approvals: 2
- EU medicines: 2
Recruiting Now
Newest start dates first, of 57 recruiting on ClinicalTrials.gov ↗- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living…NCT07830329 · Phase 2 · Regeneron Pharmaceuticals · starts Oct 29, 2026
- A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSNCT07855276 · Phase 1 · Novartis Pharmaceuticals · starts Oct 29, 2026
- A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis…NCT07812116 · Phase 2 · Sanofi · starts Oct 19, 2026
- Safety and Efficacy of Soquelitinib in Adults With Hidradenitis SuppurativaNCT07828860 · Phase 1 · Corvus Pharmaceuticals, Inc. · starts Sep 17, 2026
- Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis SuppurativaNCT07689188 · Phase 2 · Harrison Dermatology · starts Sep 10, 2026
- The Safety and Efficacy of Roflumilast Foam in HSNCT07263230 · Phase 2 · Beth Israel Deaconess Medical Center · starts Sep 1, 2026
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)NCT07766005 · Phase 2 · Spyre Therapeutics, Inc. · starts Sep 1, 2026
- ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis SuppurativaNCT07783542 · Phase 2 · Oruka Therapeutics, Inc. · starts Aug 21, 2026
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSNCT07665437 · Phase 3 · Novartis Pharmaceuticals · starts Jul 10, 2026
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaNCT07489573 · Phase 4 · Novartis Pharmaceuticals · starts Jun 1, 2026
Trials Authorized in Canada
The 10 newest of 57; search them all in Canada trials| Nov 12, 2026 | Hidradenitis suppurativa: a phase 2 multicenter platform study of targeted therapies for the treatment of adult subjectsABBV-295 / LUTIKIZUMAB (ABT-981) | AbbVie | Pending |
| Sep 17, 2026 | “a phase 2b, randomized, double-blind, placebo-controlled, parallel group, doseranging study to evaluate the efficacy and safety of duvakitug in adult…DUVAKITUG (SAR447189) | SANOFI-AVENTIS CANADA INC | Ongoing |
| Aug 25, 2026 | A phase 2, randomized, double-blind, placebo-controlled, parallel-group 52 week trial to investigate the efficacy and safety of olatorepatide, a glp-1/gip…OLATOREPATIDE (HS-20094) | Regeneron | Pending |
| Aug 7, 2026 | A multicenter, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of orka-002 in adult…ORKA-002 | ORUKA THERAPEUTICS, INC. | Ongoing |
| Aug 7, 2026 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-ofconcept trial to assess the efficacy and safety of spy072 in adults with moderate…SPY002-072 | SPYRE THERAPEUTICS, INC. | Ongoing |
| Jun 10, 2026 | A double-blind, double-dummy, parallel group, multicenter phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in…REMIBRUTINIB (LOU064) | Novartis Pharmaceuticals Corporation | Ongoing |
| Dec 19, 2025 | A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of nav-240 in adult participants with moderate-to-severe hidradenitis suppurativaNAV-240 | NAVIGATOR MEDICINES, INC. | Ongoing |
| Dec 15, 2025 | A phase 2, multicenter, randomized, double-blind, placebo- controlled trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis…ZASOCITINIB (TAK-279) | Takeda Pharmaceuticals USA | Ongoing |
| Dec 11, 2025 | A randomized, double-blind, placebo-controlled, phase 2, dose-finding study to investigate the efficacy and safety of sar445399 in participants with moderate…KEVZARA | SANOFI-AVENTIS CANADA INC | Ongoing |
| Nov 19, 2025 | A randomized, double-blind, placebo-controlled, phase 2, dose-finding study to investigate the efficacy and safety of sar445399 in participants with moderate…SAR445399 | SANOFI-AVENTIS CANADA INC | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 16, 2018 | HUMIRATreatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. | AbbVie, Inc. | Approved |
| Sep 9, 2015 | HUMIRATreatment of moderate to severe hidradenitis suppurativa | AbbVie, Inc. | Approved |
Medicines Authorised in the EU
Newest first| Sep 17, 2018 | Hulioadalimumab · biosimilar | Biosimilar Collaborations Ireland Limited | EMA ↗ |
| Jan 14, 2015 | Cosentyxsecukinumab | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA